Effects of Adrenomedullin on Atrial Electrophysiology and Pulmonary Vein Arrhythmogenesis

Int J Mol Sci. 2022 Nov 15;23(22):14064. doi: 10.3390/ijms232214064.

Abstract

Adrenomedullin, a peptide with vasodilatory, natriuretic, and diuretic effects, may be a novel agent for treating heart failure. Heart failure is associated with an increased risk of atrial fibrillation (AF), but the effects of adrenomedullin on atrial arrhythmogenesis remain unclear. This study investigated whether adrenomedullin modulates the electrophysiology of the atria (AF substrate) or pulmonary vein (PV; AF trigger) arrhythmogenesis. Conventional microelectrode or whole-cell patch clamps were used to study the effects of adrenomedullin (10, 30, and 100 pg/mL) on the electrical activity, mechanical response, and ionic currents of isolated rabbit PV and sinoatrial node tissue preparations and single PV cardiomyocytes. At 30 and 100 pg/mL, adrenomedullin significantly reduced the spontaneous beating rate of the PVs from 2.0 ± 0.4 to 1.3 ± 0.5 and 1.1 ± 0.5 Hz (reductions of 32.9% ± 7.1% and 44.9 ± 8.4%), respectively, and reduced PV diastolic tension by 12.8% ± 4.1% and 14.5% ± 4.1%, respectively. By contrast, adrenomedullin did not affect sinoatrial node beating. In the presence of L-NAME (a nitric oxide synthesis inhibitor, 100 μM), adrenomedullin (30 pg/mL) did not affect the spontaneous beating rate or diastolic tension of the PVs. In the single-cell experiments, adrenomedullin (30 pg/mL) significantly reduced the L-type calcium current (ICa-L) and reverse-mode current of the sodium-calcium exchanger (NCX). Adrenomedullin reduces spontaneous PV activity and PV diastolic tension by reducing ICa-L and NCX current and thus may be useful for treating atrial tachyarrhythmia.

Keywords: adrenomedullin; atrial fibrillation; calcium; heart failure; pulmonary vein.

MeSH terms

  • Adrenomedullin / pharmacology
  • Animals
  • Atrial Fibrillation*
  • Heart Atria
  • Heart Failure*
  • Pulmonary Veins*
  • Rabbits

Substances

  • Adrenomedullin

Grants and funding

This work was supported by grants from the Ministry of Science and Technology (MOST109-2314-B-038-124-MY3, MOST110-2314-B-038-127, MOST110-2314-B-038-107-MY3, MOST110-2314-B-016-037-MY3, NSTC111-2314-B-038-158, and MOST111-2314-B-281-003-MY3), Taipei Medical University-Wan Fang Hospital (111-wf-f-12, 108-wf-eva-25, 111-wf-phd-03), Ministry of National Defense-Medical Affairs Bureau (MND-MAB-D-112098), and Cathay General Hospital (CGH-MR-A11109), the Foundation for the Development of Internal Medicine in Okinawa (04-02-001).